Abstract 4064
Background
The treatment for haematological malignancies is lengthy, complex and intense, leading to potentially debilitating symptoms and reduced health-related quality of life. Patients are living longer due to advancements in early detection and significant improvements in treatment. While treatments for haematological malignancies dramatically increase survivability, many patients suffer from debilitating side effects during and following their treatment. Survivors can suffer long-term effects of both treatment and disease. They may be left with permanent, often devastating, physical impairments leading to an increased risk of other illnesses or a lower quality of life. The presentation is part of a mixed methods study and aims to deepen our understanding of the quality of lives of survivors of adult haematological malignancy. The study will contribute to the under-researched topic related to adult survivors of a haematological malignancy.
Methods
The participants (n = 11) were adults who had completed treatment for a haematological malignancy and were between 1-5 years post-treatment. A qualitative research process of inquiry was used to explore the quality of lives of survivors of haematological malignancy. In-depth face-to-face semi-structured interviews were conducted, based on the content and structure of the interviews envisaged being grounded in the findings of the quantitative phase of the study.
Results
Four themes and several subthemes were generated and reviewed from the qualitative data analysis. The key themes identified in this cohort were:(1) Physical wellbeing (2) Psychological wellbeing (3) Independence and (4) Supportive care needs.
Conclusions
Enhancing these survivors’ physical, psychological wellbeing, an understanding of what independence means to them and addressing supportive care needs can optimise their QoL. Knowledge and understanding of these factors and addressing these needs may provide an insight into implementation measures to enhance the same.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Royal Bournemouth Hospital and Bournemouth University.
Funding
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2743 - The Impact of Targeted Therapies and Immunotherapy in Melanoma Brain Metastases: a Systematic Review and Meta-Analysis
Presenter: Mario Mandala
Session: Poster Display session 3
Resources:
Abstract
5479 - Intracranial Anti-Tumor Activity in Melanoma Brain Metastases with Encorafenib Plus Binimetinib: A Multicenter, Retrospective Analysis
Presenter: Jose Lutzky
Session: Poster Display session 3
Resources:
Abstract
3560 - Outcomes of Patients with Melanoma Brain Metastases (MBM) Treated with Standard of Care Therapy After Being Excluded from MBM-Specific Clinical Trials
Presenter: Kourtney Holbrook
Session: Poster Display session 3
Resources:
Abstract
3175 - The analysis of current treatment outcomes in melanoma patients with brain metastases
Presenter: Joanna Placzke
Session: Poster Display session 3
Resources:
Abstract
4550 - A multivariate model to define prognostic groups among patients with melanoma brain metastases: a 10-year retrospective cohort study
Presenter: Giacomo Pelizzari
Session: Poster Display session 3
Resources:
Abstract
4191 - The immune landscape of melanoma significantly influences survival in patients with highly mutated tumors.
Presenter: Robert Ferguson
Session: Poster Display session 3
Resources:
Abstract
1625 - Final Results from Phase II of Combination with Canerpaturev (formerly HF10), an Oncolytic Viral Immunotherapy, and Ipilimumab in Unresectable or Metastatic Melanoma in 2nd-or later line treatment
Presenter: Kenji Yokota
Session: Poster Display session 3
Resources:
Abstract
5346 - Evaluating polygenic risk score prediction model for melanoma prognosis
Presenter: Miriam Potrony
Session: Poster Display session 3
Resources:
Abstract
5477 - Impact of sarcopenia in patients with metastatic melanoma treated with immunotherapy
Presenter: Maria Grazia Vitale
Session: Poster Display session 3
Resources:
Abstract
3469 - Ancillary evaluation of systemic immune antitumor response (SIAR) and tumor growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase 1 study Mel-Ipi-Rx.
Presenter: Celine Boutros
Session: Poster Display session 3
Resources:
Abstract